Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00175227
Status:
COMPLETED
Last Update Posted:
2011-05-10
First Post:
2005-09-10
Brief Title:
Prevention of Contrast-Induced Nephropathy
Sponsor:
University of Alberta
Organization:
University of Alberta
Study Overview
Official Title:
Prevention of Contrast-Induced Nephropathy a Randomized Controlled Trial of Saline Furosemide Mannitol in High Risk Patients Undergoing Cardiac Angiography
Status:
COMPLETED
Status Verified Date:
2011-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with pre-existing kidney disease are at high risk of acute renal failure when exposed to radio-contrast dyes for example during a cardiac angiogram
The investigators hypothesize that an infusion of saline furosemide mannitol will reduce rates of contrast-induced nephropathy when compared with saline infusion controls
The investigators hypothesize that an infusion of saline furosemide mannitol will reduce rates of contrast-induced nephropathy when compared with saline infusion controls
Detailed Description:
Patients with pre-existing kidney disease are at high risk of acute renal failure when exposed to radio-contrast dyes for example during a cardiac angiogram
We hypothesize that an infusion of saline furosemide mannitol will reduce rates of contrast-induced nephropathy when compared with saline infusion controls
We define an episode of contrast nephropathy using the conventional often published definition of a 25 relative increase in serum creatinine OR a 44 umol absolute increase in serum creatinine within 48 hours of contrast exposure
We hypothesize that an infusion of saline furosemide mannitol will reduce rates of contrast-induced nephropathy when compared with saline infusion controls
We define an episode of contrast nephropathy using the conventional often published definition of a 25 relative increase in serum creatinine OR a 44 umol absolute increase in serum creatinine within 48 hours of contrast exposure
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None